13F filerCIK 1536411 ↗

Duquesne Family Office

You are looking at Q3 2025. See the latest, Q3 2026 →

Reported value

$4.06B

−0.2% on the quarter before

Positions

65

29 new, 33 sold out

Top 10

53.9%

of the value

Est. gain

+$194.1M

on stocks held all quarter

Est. return

+8.0%

on those stocks since Q2 2025

Filed

Nov 14, 2025

On SEC EDGAR ↗

Positions as of Sep 30, 2025, from Duquesne Family Office's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2025. Striped tiles are options.

41 others24%
Natera Inc13%
Insmed Inc8.6%
Teva Pharmaceutical Inds Ltd8.3%
TSMC5.3%
Woodward Inc3.9%
Coupang Inc3.7%
MercadoLibre3.4%DocuSign3.0%
Verona Pharma Plc2.6%
Ishares Tr2.5%
Amazon2.4%
Roku Inc2.0%
Figure Technology Solutio1.9%
Restaurant Brands Intl Inc1.8%
Stubhub Hldgs Inc1.8%
Wabtec1.5%
SPDR S&P 500 ETF Tr1.5%
Meta1.4%
Newamsterdam Pharma Company1.3%
Ishares Tr1.3%
Carpenter Technology Corp1.3%
Citigroup Inc1.3%
Twilio1.3%
Bank America Corp1.3%

Largest buys

Since Q2 2025, sized at quarter-end prices.

  1. Ishares Tr~$101.5MNew, 0.0% → 2.5% of the portfolio+1,900,000 shares
  2. Amazon~$96.0MNew, 0.0% → 2.4% of the portfolio+437,070 shares
  3. Figure Technology Solutio~$77.0MNew, 0.0% → 1.9% of the portfolio+2,116,825 shares
  4. Stubhub Hldgs Inc~$71.7MNew, 0.0% → 1.8% of the portfolio+4,259,516 shares
  5. Meta~$55.9MNew, 0.0% → 1.4% of the portfolio+76,100 shares
  6. GE Vernova~$47.5MNew, 0.0% → 1.2% of the portfolio+77,320 shares
  7. Crh Plc~$47.2MNew, 0.0% → 1.2% of the portfolio+393,820 shares
  8. Vistra~$45.8MNew, 0.0% → 1.1% of the portfolio+233,985 shares
  9. Bank America Corp~$33.4MAdded, 0.4% → 1.3% of the portfolio+647,350 shares
  10. Cleveland-Cliffs Inc New~$33.1MNew, 0.0% → 0.8% of the portfolio+2,715,035 shares

Largest sells

Since Q2 2025, sized at quarter-end prices.

  1. Philip Morris Intl Inc~$148.6MSold out, 3.7% → 0.0% of the portfolio−815,975 shares
  2. Entegris~$132.7MSold out, 3.3% → 0.0% of the portfolio−1,645,885 shares
  3. Coherent Corp~$103.3MSold out, 2.5% → 0.0% of the portfolio−1,157,840 shares
  4. Microsoft~$99.9MSold out, 2.5% → 0.0% of the portfolio−200,930 shares
  5. Eli Lilly~$78.5MSold out, 1.9% → 0.0% of the portfolio−100,675 shares
  6. Warner Bros Discovery Inc~$74.9MSold out, 1.8% → 0.0% of the portfolio−6,537,160 shares
  7. Flutter Entmt Plc~$73.7MCut, 2.8% → 0.7% of the portfolio−290,075 shares
  8. Woodward Inc~$54.6MCut, 5.1% → 3.9% of the portfolio−215,895 shares
  9. Select Sector SPDR Tr~$51.6MSold out, 1.3% → 0.0% of the portfolio−985,300 shares
  10. Caesars Entertainment Inc Ne~$39.6MSold out, 1.0% → 0.0% of the portfolio−1,395,875 shares

Holdings

As of Sep 30, 2025; changes in shares since Jun 30, 2025.

Positions, sorted by share of the portfolio
HoldingValue
Natera IncCOM · shares +4.2% · price −4.7%12.7%$517.4M−$24.6M
Insmed IncCOM PAR $.01 · shares +7.5% · price +43.1%8.6%$349.0M+$97.7M
Teva Pharmaceutical Inds LtdSPONSORED ADS · shares +3.9% · price +20.5%8.3%$335.2M+$54.9M
TSMCSPONSORED ADS · shares 0% · price +23.3%5.3%$213.7M+$40.4M
Woodward IncCOM · shares −25% · price +3.1%3.9%$160.0M+$4.8M
Coupang IncCL A · shares +13% · price +7.5%3.7%$149.2M+$9.2M
MercadoLibreCOM · shares +8.6% · price −10.6%3.4%$136.3M−$14.9M
DocuSignCOM · shares +31% · price −7.4%3.0%$121.5M−$7.5M
Verona Pharma PlcSPONSORED ADS · shares 0% · price +12.8%2.6%$106.9M+$12.2M
Ishares TrMSCI EMG MKT ETF · shares New2.5%$101.5M—
AmazonCOM · shares New2.4%$96.0M—
Roku IncCOM CL A · shares −25% · price +13.9%2.0%$82.3M+$10.1M
Figure Technology SolutioCOM CL A · shares New1.9%$77.0M—
Restaurant Brands Intl IncCOM · shares +51% · price −3.2%1.8%$72.6M−$1.6M
Stubhub Hldgs IncCL A · shares New1.8%$71.7M—
WabtecCOM · shares +77% · price −4.2%1.5%$60.6M−$1.5M
SPDR S&P 500 ETF TrCALLTR UNIT · shares 0%1.5%$60.0M—
MetaCL A · shares New1.4%$55.9M—
Newamsterdam Pharma CompanyORDINARY SHARES · shares +131% · price +57.0%1.3%$54.7M+$8.6M
Ishares TrCALLRUSSELL 2000 ETF · shares −33%1.3%$54.7M—
Carpenter Technology CorpCOM · shares +74% · price −11.2%1.3%$54.0M−$3.9M
Citigroup IncCOM NEW · shares −23% · price +19.2%1.3%$52.3M+$8.4M
TwilioCL A · shares +156% · price −19.5%1.3%$51.3M−$4.9M
Bank America CorpCOM · shares +189% · price +9.0%1.3%$51.0M+$1.5M
SeaSPONSORD ADS · shares −11% · price +11.7%1.2%$49.0M+$5.2M
Total 65 positions100%$4.06B+$194.1M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2025 to Q3 2025: 33 stocks held throughout, up $194.1M (+8.0%).

  1. Insmed Inc+$97.7M+43%
  2. Teva Pharmaceutical Inds Ltd+$54.9M+21%
  3. TSMC+$40.4M+23%
  4. Verona Pharma Plc+$12.2M+13%
  5. Roku Inc+$10.1M+14%
  6. Twilio−$4.9M−20%
  7. Unity Software Inc1:2 split−$7.4M−17%
  8. DocuSign−$7.5M−7%
  9. MercadoLibre−$14.9M−11%
  10. Natera Inc−$24.6M−5%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.

Reported value by quarter

Pick a quarter to see what the fund held then.

$6.00B$3.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$4.47B−14%SEC ↗
Q2 2026$5.21B+54%SEC ↗
Q1 2026$3.38B−25%SEC ↗
Q4 2025$4.49B+11%SEC ↗
Q3 2025$4.06B−0%SEC ↗
Q2 2025$4.07B+33%SEC ↗
Q1 2025$3.06B−18%SEC ↗
Q4 2024$3.72B+26%SEC ↗
Q3 2024$2.95B+1%SEC ↗
Q2 2024$2.92B−34%SEC ↗
Q1 2024$4.39B+31%SEC ↗
Q4 2023$3.35B+20%SEC ↗
Q3 2023$2.79B−3%SEC ↗
Q2 2023$2.87B+25%SEC ↗
Q1 2023$2.31B+14%SEC ↗
Q4 2022$2.02B+15%SEC ↗
Q3 2022$1.76B+28%SEC ↗
Q2 2022$1.38B−40%SEC ↗
Q1 2022$2.31B−16%SEC ↗
Q4 2021$2.76B−10%SEC ↗
Q3 2021$3.08B−24%SEC ↗
Q2 2021$4.04B−11%SEC ↗
Q1 2021$4.53B+22%SEC ↗
Q4 2020$3.71B+8%SEC ↗
Q3 2020$3.44B+5%SEC ↗
Q2 2020$3.27B+32%SEC ↗
Q1 2020$2.47B−28%SEC ↗
Q4 2019$3.41B+33%SEC ↗
Q3 2019$2.57B−24%SEC ↗
Q2 2019$3.37B−2%SEC ↗
Q1 2019$3.45B+100%SEC ↗
Q4 2018$1.73B−18%SEC ↗
Q3 2018$2.10B+2%SEC ↗
Q2 2018$2.07B+14%SEC ↗
Q1 2018$1.81B−9%SEC ↗
Q4 2017$1.98B−10%SEC ↗
Q3 2017$2.20B+18%SEC ↗
Q2 2017$1.87B+22%SEC ↗
Q1 2017$1.52B+49%SEC ↗
Q4 2016$1.03B−9%SEC ↗
Q3 2016$1.13B+30%SEC ↗
Q2 2016$870.7M−35%SEC ↗
Q1 2016$1.34BSEC ↗

Subscribe to TheInference for free